Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal …
Over the last 12 months, insiders at Eli Lilly and Company have bought $0 and sold $2.35B worth of Eli Lilly and Company stock.
On average, over the past 5 years, insiders at Eli Lilly and Company have bought $638.14M and sold $5.48B worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 29,992,668 shares for transaction amount of $374.91M was made by Kearny Acquisition Corp (director) on 2022‑11‑30.
2024-11-08 | Sale | SVP, Finance, & CAO | 900 <0.0001% | $803.38 | $723,042 | -4.71% | ||
2024-09-03 | Sale | 10 percent owner | 24,084 0.0026% | $966.69 | $23.28M | -9.85% | ||
2024-08-27 | Sale | 10 percent owner | 24,552 0.0026% | $968.46 | $23.78M | -7.28% | ||
2024-08-26 | Sale | SVP, Finance, & CAO | 750 <0.0001% | $950.00 | $712,500 | -6.84% | ||
2024-08-22 | Sale | 10 percent owner | 3,196 0.0003% | $966.33 | $3.09M | -7.15% | ||
2024-07-10 | Sale | 10 percent owner | 210,000 0.023% | $939.82 | $197.36M | 0.00% | ||
2024-07-08 | Sale | 10 percent owner | 93,593 0.01% | $918.64 | $85.98M | 0.00% | ||
2024-07-05 | Sale | 10 percent owner | 52,369 0.0056% | $915.18 | $47.93M | 0.00% | ||
2024-07-03 | Sale | 10 percent owner | 8,848 0.0009% | $915.31 | $8.1M | 0.00% | ||
2024-07-01 | Sale | 10 percent owner | 58,749 0.0063% | $915.26 | $53.77M | 0.00% | ||
2024-06-28 | Sale | 10 percent owner | 1,441 0.0002% | $915.02 | $1.32M | 0.00% | ||
2024-06-25 | Sale | 10 percent owner | 188,100 0.0198% | $903.82 | $170.01M | -2.30% | ||
2024-06-24 | Sale | 10 percent owner | 17,229 0.0018% | $902.38 | $15.55M | -0.63% | ||
2024-06-20 | Sale | 10 percent owner | 9,671 0.0011% | $902.67 | $8.73M | -0.17% | ||
2024-06-17 | Sale | 10 percent owner | 194,978 0.021% | $885.91 | $172.73M | +0.06% | ||
2024-06-14 | Sale | 10 percent owner | 15,022 0.0016% | $882.47 | $13.26M | +0.78% | ||
2024-06-10 | Sale | 10 percent owner | 75,510 0.0079% | $860.78 | $65M | +2.22% | ||
2024-06-07 | Sale | 10 percent owner | 139,490 0.0147% | $852.29 | $118.89M | +3.99% | ||
2024-06-06 | Sale | 10 percent owner | 179,617 0.0189% | $837.82 | $150.49M | +5.53% | ||
2024-06-05 | Sale | 10 percent owner | 20,383 0.0022% | $836.32 | $17.05M | +6.20% |
LECHLEITER JOHN C | former director | 160068 0.0169% | $767.76 | 1 | 2 | <0.0001% |
Ricks David A | President & CEO | 157405 0.0166% | $767.76 | 1 | 6 | +34.48% |
Skovronsky Daniel | SVP, CSO, and Pres. LRL | 75818 0.008% | $767.76 | 2 | 0 | +34.08% |
TAI JACKSON P | 62857 0.0066% | $767.76 | 12 | 0 | +14.08% | |
White Anne E. | EVP & Pres, Lilly Neuroscience | 57926 0.0061% | $767.76 | 1 | 2 | +34.48% |
Lilly Endowment | $76.94B | 10.41 | 98.9M | -0.87% | -$676.83M | 100 | |
The Vanguard Group | $56.59B | 7.65 | 72.75M | +1.58% | +$882.06M | 1.04 | |
BlackRock | $50.78B | 6.87 | 65.27M | +1.41% | +$706.35M | 1.11 | |
PNC Financial Services | $40.02B | 5.41 | 51.44M | -0.53% | -$211.04M | 27.99 | |
State Street | $26.65B | 3.61 | 34.26M | +1.4% | +$366.61M | 1.09 |